INNATE PHARMA SA-SPONS ADR (IPHA) Fundamental Analysis & Valuation

NASDAQ:IPHA • US45781K2042

Current stock price

1.41 USD
+0.04 (+2.92%)
Last:

This IPHA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. IPHA Profitability Analysis

1.1 Basic Checks

  • In the past year IPHA has reported negative net income.
  • In the past year IPHA has reported a negative cash flow from operations.
  • In the past 5 years IPHA always reported negative net income.
  • IPHA had a negative operating cash flow in each of the past 5 years.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -78.41%, IPHA is not doing good in the industry: 68.60% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -78.41%
ROE N/A
ROIC N/A
ROA(3y)-42.35%
ROA(5y)-34.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 -400

1.3 Margins

  • IPHA's Gross Margin of 1.29% is fine compared to the rest of the industry. IPHA outperforms 70.16% of its industry peers.
  • In the last couple of years the Gross Margin of IPHA has declined.
  • The Profit Margin and Operating Margin are not available for IPHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-75.94%
GM growth 5Y-57.54%
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. IPHA Health Analysis

2.1 Basic Checks

  • IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IPHA has been increased compared to 1 year ago.
  • IPHA has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for IPHA is higher compared to a year ago.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • IPHA has an Altman-Z score of -11.37. This is a bad value and indicates that IPHA is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -11.37, IPHA is doing worse than 75.97% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -11.37
ROIC/WACCN/A
WACC7.35%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 1.27 indicates that IPHA should not have too much problems paying its short term obligations.
  • IPHA has a Current ratio of 1.27. This is amonst the worse of the industry: IPHA underperforms 84.11% of its industry peers.
  • IPHA has a Quick Ratio of 1.27. This is a normal value and indicates that IPHA is financially healthy and should not expect problems in meeting its short term obligations.
  • IPHA has a worse Quick ratio (1.27) than 83.53% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.27
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IPHA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 10.35% over the past year.
  • Looking at the last year, IPHA shows a very negative growth in Revenue. The Revenue has decreased by -77.92% in the last year.
  • Measured over the past years, IPHA shows a very negative growth in Revenue. The Revenue has been decreasing by -45.15% on average per year.
EPS 1Y (TTM)10.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.82%
Revenue 1Y (TTM)-77.92%
Revenue growth 3Y-61.69%
Revenue growth 5Y-45.15%
Sales Q2Q%-74.22%

3.2 Future

  • The Earnings Per Share is expected to decrease by -12.83% on average over the next years. This is quite bad
  • Based on estimates for the next years, IPHA will show a very strong growth in Revenue. The Revenue will grow by 46.26% on average per year.
EPS Next Y13.33%
EPS Next 2Y-32.12%
EPS Next 3Y-12.83%
EPS Next 5YN/A
Revenue Next Year-2.22%
Revenue Next 2Y-22.02%
Revenue Next 3Y30.65%
Revenue Next 5Y46.26%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8

More info and screens

Find the best growth stocksShow best growing peers

0

4. IPHA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • IPHA's earnings are expected to decrease with -12.83% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-32.12%
EPS Next 3Y-12.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IPHA Dividend Analysis

5.1 Amount

  • IPHA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IPHA Fundamentals: All Metrics, Ratios and Statistics

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (4/24/2026, 4:30:02 PM)

1.41

+0.04 (+2.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-01
Earnings (Next)N/A
Inst Owners8.34%
Inst Owner Change-0.3%
Ins Owners1.22%
Ins Owner ChangeN/A
Market Cap132.30M
Revenue(TTM)2.79M
Net Income(TTM)-49.18M
Analysts82.5
Price Target7.01 (397.16%)
Short Float %0.11%
Short Ratio3.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.31%
PT rev (3m)-4.66%
EPS NQ rev (1m)-5.99%
EPS NQ rev (3m)-4.23%
EPS NY rev (1m)-2.06%
EPS NY rev (3m)-0.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-28.7%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 40.59
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.66
OCFYN/A
SpS0.03
BVpS-0.27
TBVpS-0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -78.41%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1.29%
FCFM N/A
ROA(3y)-42.35%
ROA(5y)-34.95%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-75.94%
GM growth 5Y-57.54%
F-Score0
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.12%
Cap/Sales 5.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.27
Altman-Z -11.37
F-Score0
WACC7.35%
ROIC/WACCN/A
Cap/Depr(3y)25.32%
Cap/Depr(5y)21.48%
Cap/Sales(3y)4.22%
Cap/Sales(5y)5.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.82%
EPS Next Y13.33%
EPS Next 2Y-32.12%
EPS Next 3Y-12.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-77.92%
Revenue growth 3Y-61.69%
Revenue growth 5Y-45.15%
Sales Q2Q%-74.22%
Revenue Next Year-2.22%
Revenue Next 2Y-22.02%
Revenue Next 3Y30.65%
Revenue Next 5Y46.26%
EBIT growth 1Y0.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year767.26%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-625.88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-665.01%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA-SPONS ADR / IPHA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to IPHA.


Can you provide the valuation status for INNATE PHARMA SA-SPONS ADR?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.


How profitable is INNATE PHARMA SA-SPONS ADR (IPHA) stock?

INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.


How financially healthy is INNATE PHARMA SA-SPONS ADR?

The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 1 / 10.